RESEARCH USE AND EDUCATIONAL DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
Semaglutide is a GLP-1 receptor agonist with a substantial clinical research record. Different trials have examined body weight, cardiovascular events, kidney disease and liver histology. These outcomes should not be blended into a single claim of general metabolic benefit: each study enrolled a defined population and measured specific endpoints. This article reviews four major reports and explains what their findings establish within those boundaries. [1–4]
BODY-WEIGHT RESEARCH IN STEP 1
Wilding and colleagues reported STEP 1 in 2021, a randomized trial of 1,961 adults with overweight or obesity without diabetes. Both groups received lifestyle intervention. At 68 weeks, mean weight reduction was 14.9% with semaglutide and 2.4% with placebo. [1]
The result concerns an average under the trial conditions; it does not predict an individual outcome. It also measures total body weight, not an identical percentage of body fat. Body composition, physical function and long-term maintenance are separate questions that require their own measurements.
STEP 1 is useful evidence for its weight-management question, but it should not be used alone to infer prevention of heart attacks or kidney failure. Those outcomes need trials designed to measure the events themselves.
CARDIOVASCULAR EVENTS IN SELECT
Lincoff and colleagues published SELECT in 2023. It enrolled 17,604 adults with established cardiovascular disease and overweight or obesity but without diabetes. Over an average follow-up of about forty months, the primary composite outcome occurred in 6.5% of the semaglutide group and 8.0% of the placebo group. The composite included cardiovascular death, nonfatal heart attack or nonfatal stroke. [2]
The reported hazard ratio was 0.80. That is a relative comparison over time, not a twenty-percentage-point absolute reduction. The observed event percentages differed by 1.5 percentage points. Adverse events leading to permanent discontinuation were also more frequent with semaglutide: 16.6% versus 8.2%. [2]
SELECT provides evidence beyond a change in weight or a laboratory marker. Its participants already had cardiovascular disease, however, so the results should not be described as proof of the same benefit in every otherwise healthy population.
KIDNEY OUTCOMES IN FLOW
Perkovic and colleagues reported FLOW in 2024. The trial randomized 3,533 people with type 2 diabetes and chronic kidney disease. Median follow-up was 3.4 years, with early stopping recommended after a planned interim analysis. [3]
There were 331 first primary-outcome events with semaglutide and 410 with placebo, corresponding to a hazard ratio of 0.76. The composite included kidney failure, a major sustained reduction in estimated filtration, or death from kidney-related or cardiovascular causes. This should not be shortened into a claim that semaglutide improved kidney function by twenty-four percent. [3]
The study reported slower average decline in estimated filtration, while serious adverse events occurred in 49.6% and 53.8% of the groups, respectively. These findings concern people with established diabetic kidney disease; they do not establish kidney enhancement in healthy individuals. [3]
LIVER HISTOLOGY IN ESSENCE
Sanyal and colleagues reported an interim analysis of ESSENCE in 2025. The analysis covered the first 800 participants evaluated at 72 weeks in a larger trial enrolling people with biopsy-defined metabolic dysfunction-associated steatohepatitis, or MASH, and stage 2 or 3 fibrosis. [4]
One primary endpoint was improvement in fibrosis without worsening of steatohepatitis. It occurred in 36.8% of the semaglutide group and 22.4% of the placebo group. These were tissue-based findings from liver biopsies, which answer a different question from an imaging measurement of liver fat. [4]
An interim histology result does not by itself establish prevention of future liver failure or a survival benefit. Those longer-term clinical outcomes require appropriate follow-up and analysis. The distinction helps readers understand both the significance and limits of the reported improvement.
KEEPING THE FINDINGS IN CONTEXT
The cited trials were funded by Novo Nordisk and evaluated defined clinical preparations under formal protocols. Their populations, endpoints and follow-up periods differ. Combining their results into a broad promise would hide those differences and overstate what any one report shows. [1–4]
For research readers, the useful questions are what was measured, who was studied, what the comparator was and how uncertainty was handled. A statistically significant result does not establish universal benefit or absence of risk.
These publications also do not authenticate a separate laboratory batch or establish that a research-use-only material is equivalent to a clinical preparation. Products intended for qualified laboratory research remain unsuitable for human or veterinary use. The studies are presented here as an educational evidence review, not a personal-use recommendation.
REFERENCES
1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989–1002.
https://doi.org/10.1056/NEJMoa2032183
2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389:2221–2232.
https://doi.org/10.1056/NEJMoa2307563
3. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine. 2024;391:109–121.
https://doi.org/10.1056/NEJMoa2403347
4. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. New England Journal of Medicine. 2025;392:2089–2099.
https://doi.org/10.1056/NEJMoa2413258